Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.49 | 3.73 | — | — | 1.56 | — | — | — | 0.91 | — | — | — | 4.16 | 1.45 | — | 7.99 | — | — | — | — | — |
| — | — | — | — | +70.2% | — | — | — | -78.0% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.75 | 2.24 | 2.21 | 0.62 | 0.36 | 0.86 | 1.52 | 2.87 | 0.47 | 6.17 | 25.18 | 13.93 | 6.97 | 6.34 | 4.52 | 1.41 | 1.27 | 1.74 | 12.65 | 17.35 | 20.45 |
| — | +160.5% | +45.6% | -78.5% | -21.9% | -86.1% | -94.0% | -79.4% | -93.3% | -2.7% | +456.7% | +887.8% | +447.5% | +264.2% | -64.3% | -91.9% | -93.8% | -86.7% | -53.1% | +193.7% | +3.8% | |
| P/B Ratio | 4.68 | 6.85 | 8.65 | 1.83 | 1.59 | 1.64 | 1.01 | 1.75 | 1.72 | 4.61 | 8.64 | 3.91 | 1.50 | 1.94 | 4.06 | 2.90 | 1.73 | 1.27 | 3.03 | 4.10 | 4.40 |
| — | +318.2% | +755.9% | +4.3% | -7.9% | -64.4% | -88.3% | -55.2% | +15.2% | +137.2% | +113.0% | +34.8% | -13.5% | +52.8% | +33.8% | -29.2% | -60.7% | -74.9% | -41.7% | -2.6% | -6.6% | |
| P/FCF | — | — | — | 0.59 | — | — | — | — | 0.87 | — | — | — | — | — | — | 3.56 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 0.77 | — | — | — | 0.27 | — | — | — | — | — | — | 5.56 | — | — | — | — | — |
| — | — | — | — | +182.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 0.78 | — | — | — | 0.27 | — | — | — | 3.34 | 1.11 | — | 7.06 | — | — | — | — | — |
| — | — | — | — | +187.9% | — | — | — | -91.8% | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.1% | -42.2% | 46.0% | 71.3% | 81.6% | 51.4% | 45.6% | 69.0% | 61.7% | 73.9% | 76.8% | -343.2% | 99.2% | 91.0% | 85.6% | 35.1% | 92.5% | 90.8% | 99.6% | -301.5% | -228.7% |
| — | -182.1% | +0.8% | +3.3% | +32.3% | -30.4% | -40.5% | +120.1% | -37.8% | -18.9% | -10.3% | -1078.0% | +7.3% | +0.3% | -14.0% | +111.6% | +140.4% | +211.5% | +146.3% | -1628.9% | -328.7% | |
| Operating Margin | -48.7% | -42.2% | -161.0% | -29.3% | 25.6% | -165.3% | -323.1% | -298.0% | 48.9% | -538.9% | -590.4% | -460.4% | -341.5% | -342.3% | -156.9% | 16.4% | -59.8% | -160.8% | -624.4% | -411.6% | -338.3% |
| — | +74.5% | +50.2% | +90.2% | -47.7% | +69.3% | +45.3% | +35.3% | +114.3% | -57.4% | -276.4% | -2908.5% | -471.1% | -112.9% | +74.9% | +104.0% | +82.3% | -22.8% | -105.5% | -9895.4% | -63.0% | |
| Net Margin | -49.9% | 59.4% | -177.0% | -34.3% | 23.1% | -163.0% | -311.1% | -87.0% | 50.9% | -515.6% | -573.3% | -429.8% | 168.8% | 437.5% | -155.2% | 17.5% | -59.5% | -158.8% | -620.7% | -410.1% | -337.7% |
| — | +136.5% | +43.1% | +60.5% | -54.6% | +68.4% | +45.7% | +79.8% | -69.9% | -217.8% | -269.5% | -2554.0% | +384.0% | +375.5% | +75.0% | +104.3% | +82.4% | -22.3% | -104.4% | -10254.9% | -63.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -86.9% | 60.9% | -95.8% | -23.1% | 29.6% | -57.7% | -42.1% | -13.1% | 63.3% | -67.9% | -40.3% | -26.6% | 9.6% | 40.9% | -30.3% | 9.7% | -18.7% | -25.8% | -31.7% | -21.9% | -17.3% |
| — | +205.6% | -127.8% | -76.8% | -53.2% | +15.1% | -4.2% | +50.9% | +559.1% | -265.9% | -33.3% | -375.1% | +151.4% | +258.9% | +4.6% | +144.2% | -7.9% | -115.9% | -99.9% | -2975.5% | -29.6% | |
| ROA | -28.8% | 6.9% | -15.5% | -5.4% | 6.5% | -15.4% | -16.9% | -5.9% | 24.2% | -24.8% | -19.1% | -14.4% | 5.4% | 17.7% | -12.0% | 5.3% | -12.0% | -16.9% | -21.8% | -16.0% | -12.9% |
| — | +144.9% | +8.2% | +8.5% | -73.1% | +37.7% | +11.6% | +59.4% | +344.8% | -239.9% | -59.0% | -373.3% | +145.3% | +204.9% | +45.0% | +133.1% | +7.2% | -82.0% | -73.4% | -2778.6% | -25.9% | |
| ROIC | -144.1% | — | -52.1% | -14.1% | 59.1% | -117.6% | — | — | — | -128.8% | -55.4% | -33.1% | -22.6% | -404.9% | — | 13.9% | -18.2% | -20.9% | -33.7% | -32.5% | -27.9% |
| — | — | — | — | — | +8.7% | — | — | — | +68.2% | — | -337.3% | -24.1% | -1833.4% | — | +142.9% | +34.6% | -10.3% | -33.3% | -2517.3% | -2.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.92 | 0.82 | 1.72 | 1.92 | 0.55 | 2.31 | 0.47 | 0.32 | 0.28 | 0.59 | 0.32 | 0.22 | 0.18 | 0.20 | 0.32 | 0.25 | 0.18 | 0.16 | 0.14 | 0.11 | 0.09 |
| — | -64.5% | +263.7% | +495.0% | +94.5% | +291.5% | +47.8% | +45.0% | +61.5% | +194.4% | +1.3% | -9.2% | -1.8% | +22.8% | +131.4% | +130.8% | +96.6% | +88.4% | +67.7% | +7.5% | -6.7% | |
| Debt / EBITDA | — | — | — | — | 1.81 | — | — | — | 0.61 | — | — | — | — | — | — | 2.29 | — | — | — | — | — |
| — | — | — | — | +197.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.10 | 2.96 | 1.90 | 5.10 | 5.22 | 5.25 | 3.28 | 3.92 | 3.75 | 2.71 | 3.63 | 4.48 | 5.68 | 5.64 | 6.33 | 4.57 | 2.95 | 3.29 | 3.25 | 3.75 | 4.86 |
| — | -43.7% | -42.1% | +30.2% | +39.3% | +93.9% | -9.6% | -12.6% | -34.0% | -51.9% | -42.7% | -2.0% | +92.3% | +71.2% | +94.8% | +21.9% | -39.2% | -37.2% | -54.0% | -39.2% | -21.4% | |
| Quick Ratio | 4.92 | 2.96 | 1.80 | 4.92 | 5.02 | 5.02 | 3.11 | 3.92 | 3.69 | 2.69 | 3.61 | 4.46 | 5.66 | 5.61 | 6.30 | 4.54 | 2.93 | 3.24 | 3.18 | 3.69 | 4.80 |
| — | -41.1% | -42.1% | +25.6% | +36.0% | +86.4% | -13.7% | -12.1% | -34.8% | -52.0% | -42.7% | -1.8% | +93.0% | +73.3% | +98.0% | +23.1% | -39.0% | -37.2% | -54.2% | -40.2% | -22.4% | |
| Interest Coverage | -7.85 | -14.84 | -6.52 | -2.50 | 6.03 | -44.07 | -449.95 | — | — | -9276.33 | -45.06 | — | — | 75.25 | -56.94 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MGNX stock.
MacroGenics, Inc.'s current P/E is -3.5x. The average P/E over the last 2 quarters is 2.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
MacroGenics, Inc.'s current operating margin is -48.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking MacroGenics, Inc.'s business trajectory between earnings reports.